Medpace
MEDP
Market cap $8.51B

295.92 USD

+0.15

0.05%

Updated May 22, 12:37 PM EDT

1 day

0.05%

5 days

-0.48%

1 month

4.83%

3 months

-14.06%

6 months

-12.38%

Year to date

-11.60%

1 year

-24.09%

5 years

221.02%

10 years

964.84%

About: Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the US, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Employees: 5,900

Healthcare Diagnostics & Research

0

Funds holding %

of 7,245 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

10% more repeat investments, than reductions

Existing positions increased: 227 | Existing positions reduced: 206

0.93% more ownership

Funds ownership: 81.38% [Q4 2024] → 82.3% (+0.93%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]

1% less first-time investments, than exits

New positions opened: 66 | Existing positions closed: 67

2% less funds holding

Funds holding: 579 [Q4 2024] → 567 (-12) [Q1 2025]

9% less capital invested

Capital invested by funds: $8.4B [Q4 2024] → $7.64B (-$768M) [Q1 2025]

34% less call options, than puts

Call options by funds: $14.5M | Put options by funds: $22M

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$300

1%

upside

Avg. target

$325

10%

upside

High target

$355

20%

upside

5 analyst ratings

1 positive

20%

4 neutral

80%

0 negative

0%

Truist Securities Jailendra Singh	1%upside $300	Hold Maintained	23 Apr 2025
Baird Eric Coldwell	6%upside $313	Neutral Maintained	23 Apr 2025
TD Cowen Charles Rhyee	11%upside $328	Hold Downgraded	14 Apr 2025
Mizuho Ann Hynes	20%upside $355	Outperform Maintained	9 Apr 2025
Leerink Partners Michael Cherny	12%upside $330	Market Perform Initiated	24 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about MEDP published over the past 30 days

Zacks Investment Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Investment Research

CON or MEDP: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?

CON or MEDP: Which Is the Better Value Stock Right Now?

Medpace Holdings, Inc. (MEDP) Q1 2025 Earnings Call Transcript

Medpace Holdings, Inc. (NASDAQ:MEDP ) Q1 2025 Earnings Conference Call April 22, 2025 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive Officer Jesse Geiger - President Kevin Brady - Chief Financial Officer Conference Call Participants David Windley - Jefferies Max Smock - William Blair Ann Hynes - Mizuho Dan Leonard - UBS Eric Coldwell - Baird Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Jailendra Singh - Truist Securities Justin Bowers - Deutsche Bank Operator Good day, ladies and gentlemen, and welcome to the Medpace First Quarter 2025 Earnings Conference Call. At this time all participants are in a listen-only mode.

Medpace Holdings, Inc. (MEDP) Q1 2025 Earnings Call Transcript

Investors Business Daily

Medpace Hits 17-Month Low After Bookings Miss Leaves Investors Mystified

Medpace stock tumbled Tuesday after lighter-than-expected bookings in the March quarter "cast more doubt on the path forward."

Medpace Hits 17-Month Low After Bookings Miss Leaves Investors Mystified

Zacks Investment Research

Medpace (MEDP) Q1 Earnings and Revenues Beat Estimates

Medpace (MEDP) came out with quarterly earnings of $3.67 per share, beating the Zacks Consensus Estimate of $3.06 per share. This compares to earnings of $3.20 per share a year ago.

Medpace (MEDP) Q1 Earnings and Revenues Beat Estimates

Medpace Holdings, Inc. Reports First Quarter 2025 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue for the three months ended March 31, 2025 increased 9.3% to $558.6 million, compared to $511.0 million for the comparable prior-year period. On a constant currency basis, revenue for the first quarter of 2025 increased 9.5% compared to the first quarter of 2024. Backlog as of March 31, 2025 decre.

Medpace Holdings, Inc. Reports First Quarter 2025 Results

Zacks Investment Research

Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON) or Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Investment Research

Medpace (MEDP) Surges 9.1%: Is This an Indication of Further Gains?

Medpace (MEDP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Medpace (MEDP) Surges 9.1%: Is This an Indication of Further Gains?

Zacks Investment Research

Medpace (MEDP) Ascends While Market Falls: Some Facts to Note

In the latest trading session, Medpace (MEDP) closed at $290.10, marking a +1.04% move from the previous day.

Medpace (MEDP) Ascends While Market Falls: Some Facts to Note

See News Rankings

Charts implemented using Lightweight Charts™